Celprogen

Executive Summary

Celprogen, founded in 2004 and headquartered in Rotterdam, Netherlands, is a private biotechnology company specializing in stem cell research tools and therapeutic products for regenerative medicine. The company addresses multiple therapeutic areas including cardiology, oncology, diabetes, and neurology, and manufactures all biological products in the United States. Celprogen serves the drug discovery needs of biotech, pharmaceutical, and academic partners. Despite a long operating history, the company remains private with no disclosed funding rounds or valuation, suggesting a focus on steady organic growth rather than aggressive venture capital expansion.

Upcoming Catalysts (preview)

• TBDExpansion of stem cell product portfolio into new therapeutic indications40% success
• TBDStrategic partnership with a major pharmaceutical company for drug discovery services30% success
• TBDRegulatory milestone or clinical trial initiation for a lead therapeutic candidate20% success